There were no associations between ACE I/D or 12 other polymorphisms of hypertension susceptibility genes and clinical outcomes or treatment effect in White patients with hypertension and LVH in the LIFE study. This suggests that the observed effects of losartan versus atenolol in the LIFE study do not depend on these genotypes, at least among these White patients studied in the Scandinavian countries. sum up in one sentonce

The prevalence of hypertension in blacks is higher than in other groups. In 2009 to 2012, the age-adjusted prevalence of hypertension was 44.9% and 46.1% among non-Hispanic black men and women, respectively; 32.9% and 30.1% among non-Hispanic white men and women, respectively; and 29.6% and 29.9% among Hispanic men and women, respectivelyBlack patients of African origin have more severe and resistant hypertension. A recent study from the National Health and Nutrition survey reported that 42.8% of African-born (foreign) blacks had hypertension but only 27.4% of US-born blacks had hypertension.PROPOSE a scientifically-testable hypothesis that explains the disparity in hypertension between black patients of US-born vs. those of foreign-born status as shown in the graph below.

write literature review for genetic factors influence in hypertension using APA references

Studying the impact of a new medication on the blood pressure of patients with hypertension is an example of dependent variable.Group of answer choicesTrueFalse

Other genetic polymorphismsThe between-genotype difference for the homozygotes (A/A vs. G/G) for the b2-adrenergic receptor Arg16Gly gene for the cardiovascular death endpoint reached significance (P=0.05) (Fig. 2). Selected other comparisons approached significance (aldosterone synthase promoter C-344T, C/Cvs. T/T, stroke, P=0.06; type 1 angiotensin receptor A11 66C, A/C vs. A/A, primary composite, P=0.07; bradykinin 2 receptor I/D, I/D vs. I/I, primary composite, P=0.07; and G protein b3-subunit C825T, C/T vs. C/C, MI, P=0.07). However, most of these did not seem biologically plausible because the effects were seen in heterozygotes only, and after adjusting for multiple testing of the many endpoints (comparison with Bonferroni-adjusted P value of 0.001), no between-genotype differences were significant, suggesting that these results are most likely chance findings.Genotype-by-treatment differences between losartan and atenolol for the cardiovascular endpoints were not significant (P values 0.06–0.98, Supplementary Table 4, Supplemental Digital Content 4, http://links.lww.com/FPC/A77), with the ex- ception of cardiovascular death for the b2-adrenergic receptor Gln27Glu genotype (P=0.02) (Supplemental Table 4d, Sup- plemental Digital Content 4, http://links.lww.com/FPC/A77). Again, this is likely a chance finding because the P values were not less than the Bonferroni-adjusted P value of 0.001.

A male patient at 75 years old is worrying about his hypertension and consulted his family doctor. His blood biochemistry results show:Analyte (SERUM)Result Day 1Result Day 3Reference intervalSodium125120135 – 145 mmol/LPotassium2.52.83.5 – 5.5 mmol/LChloride869095 – 110 mmol/LBicarbonate353222 – 32 mmol/LUrea7.07.23.0 – 8.0 mmol/LCreatinine908640 – 90 μmol/L* Urine sodium = 58 (<20 mmol/L in low sodium)In general, which medication may cause a decrease in serum potassium?Group of answer choicesPotassium-sparing diureticBeta-adrenergic blockerBeta-adrenergic agonistDigoxin